U.S., July 30 -- ClinicalTrials.gov registry received information related to the study (NCT07091695) titled 'Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab' on July 22.
Brief Summary: The purpose of this study is to understand the characteristics of adults diagnosed with with clinically palpable stage III resectable melanoma, the associated treatment patterns for their disease, and outcomes associated with the real-world use of neoadjuvant nivolumab+relatlimab or nivolumab+ipilimumab
Study Start Date: Aug. 01
Study Type: OBSERVATIONAL
Condition:
Melanoma
Intervention:
BIOLOGICAL: Nivolumab + relatlimab
As prescribed by the treating clinician
BIOLOGICAL: Nivolum...